Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.55 |
| ▸ | NPY4R | P50391 | 9/20 | 0.55 |
| ▸ | NPY1R | P25929 | 8/20 | 0.55 |
| ▸ | NPY2R | P49146 | 6/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | FURIN | P09958 | 1/20 | 0.50 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507808 | 0.96 | NPY4R (0.55) | NPY5RNPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL16508051 | 0.92 | NPY5R (0.54) | NPY5RNPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL16508043 | 0.91 | NPY4R (0.59) | NPY5RNPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL16508042 | 0.89 | NPY4R (0.58) | NPY5RNPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL16507987 | 0.88 | NPY4R (0.59) | NPY5RNPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL22133174 | 0.88 | NPY4R (0.57) | NPY5RNPY4RNPY1RNPY2RFURIN | |
| SCHEMBL22133048 | 0.88 | NPY4R (0.58) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL13445658 | 0.87 | NPY4R (0.58) | NPY5RNPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL29641086 | 0.87 | NPY4R (0.60) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22133047 | 0.86 | NPY4R (0.56) | NPY5RNPY4RNPY1RNPY2ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | NPY5R 1478/4885NPY4R 1387/4885NPY1R 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.